Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Rhabdomyosarcoma Market Research Report Information By Type (Embryonal & Alveolar), by Diagnosis (X-Ray, CT scan, MRI, PET scan, Bone scan, Needle & Surgical Biopsy), and by Treatment (Surgery, Radiation Therapy, Chemotherapy, Stem Cell Therapy) - Forecast Till 2030

ID: MRFR/Pharma/5107-HCR | 100 Pages | Author: Rahul Gotadki| April 2024

Rhabdomyosarcoma Market Scenario

The rhabdomyosarcoma market is projected to reach USD 1.74 Billion by 2030 at 3.80% CAGR during the forecast period 2022-2030 .Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.

Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.

Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.


The rhabdomyosarcoma market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma.

The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.

Imaging tests are further segmented into X-Ray, MRI scan, CT scan, PET scan, and Bone Scan.

Biopsy is further segmented into Needle Biopsy and Surgery Biopsy.

The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy. Chemotherapy is expected to account for the largest market share due to its effective treatment for minimizing the risk of cancer reoccurrence and high preference among the patients. Radiation therapy is anticipated to be the fastest growing segment due to technological advancements in the segment.

The market, by region, has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rhabdomyosarcoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rhabdomyosarcoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The rhabdomyosarcoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rhabdomyosarcoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma are some of the key players in the rhabdomyosarcoma market.

Regional Market Summary

Rhabdomyosarcoma Market Share (%), by Region, 2017

Rhabdomyosarcoma Market Share

Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)

Geographically, the Americas is anticipated to dominate the rhabdomyosarcoma market owing to growing incidences of rhabdomyosarcoma and other soft tissue cancers. According to a report published by The American Cancer Society in July 2018, in the US records approximately 400 to 500 new cases of rhabdomyosarcoma every year. Additionally, government support in this region contributes to the growth of the market.

Europe is expected to hold the second largest position in the rhabdomyosarcoma market. The market growth in this region is attributed to the increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population suffering from rhabdomyosarcoma, market players introducing new anticancer molecules in the region and raising awareness about cancer. For instance, in February 2016, Eisai Co., Ltd. received approval for developing its anticancer agent Halaven in Japan. A drug is a treatment option for treating patients suffering from soft tissue sarcomas.

On the other hand, the Middle East & Africa has the lowest market share. Majority of the market of this region is expected to be held by the Middle East region due to rising cases of rhabdomyosarcoma.

Rhabdomyosarcoma Market, by Type

  • Embryonal Rhabdomyosarcoma

  • Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma Market, by Diagnosis

  • Imaging Tests

  • X-Ray

  • CT Scan

  • MRI Scan

  • PET Scan

  • Bone Scan

  • Biopsy

  • Needle Biopsy

  • Surgical Biopsy

Rhabdomyosarcoma Market, by Treatment

  • Surgery

  • Radiation Therapy

  • Chemotherapy

  • Stem Cell Therapy

Rhabdomyosarcoma Market, by Region

  • Americas

    • North America

    • US

    • Canada

    • South America

  • Europe

    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Intended Audience

  • Pharmaceutical Companies

  • Rhabdomyosarcoma Drug Suppliers & Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Government Research Institute

  • Academic Institutes and Universities

Report Attribute/Metric Details
  Market Size   2030: USD 1.74 Billion
  CAGR   3.80% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, and Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Raising awareness of rhabdomyosarcoma and its increasing prevalence

Frequently Asked Questions (FAQ) :

Rhabdomyosarcoma Market is projected to grow at a 3.80% CAGR between 2022-2030.

The Americas is projected to command the largest share in Rhabdomyosarcoma Market.

Chemotherapy segment will dominate Rhabdomyosarcoma Market.

Increasing prevalence of rhabdomyosarcoma is boosting market growth.

Huge treatment cost may limit market growth.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization